Stockscreener 앱 받기
7.79
1.02%
-0.08
시간 외 거래:
7.80
0.010
+0.13%
전일 마감가:
$7.87
열려 있는:
$8.12
하루 거래량:
2.02M
Relative Volume:
0.89
시가총액:
$586.74M
수익:
$3.64M
순이익/손실:
$-87.37M
주가수익비율:
-1.8954
EPS:
-4.11
순현금흐름:
$-86.46M
1주 성능:
+7.75%
1개월 성능:
-23.02%
6개월 성능:
+61.95%
1년 성능:
+32.03%
1일 변동 폭
$7.74
$8.35
1주일 범위
$6.68
$8.88
52주 변동 폭
$4.01
$11.24
Verastem Inc Stock (VSTM) Company Profile
명칭
Verastem Inc
전화
(781) 292-4200
주소
117 KENDRICK STREET, NEEDHAM, MA
VSTM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
7.79 | 592.77M | 3.64M | -87.37M | -86.46M | -4.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-16 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-04-10 | 개시 | Jefferies | Buy |
| 2025-03-24 | 재확인 | H.C. Wainwright | Buy |
| 2024-12-31 | 재확인 | BTIG Research | Buy |
| 2024-09-30 | 개시 | Guggenheim | Buy |
| 2023-11-21 | 재개 | BTIG Research | Buy |
| 2023-09-27 | 개시 | B. Riley Securities | Buy |
| 2023-06-15 | 업그레이드 | Mizuho | Neutral → Buy |
| 2022-09-07 | 재개 | Alliance Global Partners | Buy |
| 2022-04-29 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-04-14 | 개시 | RBC Capital Mkts | Outperform |
| 2022-03-09 | 개시 | Truist | Buy |
| 2021-07-01 | 개시 | Alliance Global Partners | Buy |
| 2021-05-24 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2019-06-20 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2019-05-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | 개시 | BTIG Research | Buy |
| 2018-05-02 | 개시 | Seaport Global Securities | Buy |
| 2018-03-08 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-13 | 개시 | Oppenheimer | Outperform |
| 2017-03-24 | 재확인 | H.C. Wainwright | Buy |
| 2015-09-29 | 다운그레이드 | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | 다운그레이드 | Jefferies | Buy → Hold |
| 2015-09-29 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2015-09-28 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2015-09-09 | 개시 | Raymond James | Strong Buy |
| 2015-05-12 | 재확인 | UBS | Buy |
| 2015-04-08 | 개시 | H.C. Wainwright | Buy |
| 2015-01-23 | 재확인 | ROTH Capital | Buy |
| 2014-07-08 | 재개 | Oppenheimer | Perform |
| 2014-02-11 | 개시 | Mizuho | Buy |
모두보기
Verastem Inc 주식(VSTM)의 최신 뉴스
Can Verastem Inc. stock continue upward trendJuly 2025 Price Swings & Consistent Income Trade Recommendations - ulpravda.ru
Is Verastem Inc. stock attractive after correctionMarket Performance Recap & Verified Short-Term Trading Plans - ulpravda.ru
Will Verastem Inc. stock attract more institutional investorsJuly 2025 Outlook & Safe Entry Point Identification - ulpravda.ru
Verastem updates oncology strategy in new corporate presentation - TipRanks
RBC Raises Price Target on Verastem to $15 From $14, Keeps Outperform, Speculative Risk - MarketScreener
Immuneering plummets following phase 2 data of atebimetinib for pancreatic cancer - Seeking Alpha
Verastem shifts focus to KRAS G12D and pancreatic programs - MSN
Verastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects - MSN
What's Going On With Verastem Stock Friday?Verastem (NASDAQ:VSTM) - Benzinga
Verastem ends trial of Avmapki Fakzynja combo with Amgen's Lumakras in NSCLC - MSN
Verastem Ends Lung Cancer Trial, Reallocates Resources - Sahm
Verastem Oncology stock drops after hours after discontinuing a clinical trial in lung cancer - MSN
Verastem stock steady as Mizuho reiterates Outperform rating By Investing.com - Investing.com Canada
Verastem Shifts Focus to KRAS G12D and Pancreatic Programs - TipRanks
Verastem to discontinue Avmapki/Fakzynja combo in KRAS G12C-mutated NSCLC - The Pharma Letter
Verastem (VSTM) Halts Development of Avutometinib/Defactinib Com - GuruFocus
Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC (VSTM) - Seeking Alpha
Amgen stock dips as Lumakras combo trial ends; MariTide data now the next watch - ts2.tech
Verastem (NASDAQ:VSTM) Shares Cross Above 200 Day Moving AverageShould You Sell? - MarketBeat
Verastem, TEN Holdings And 3 Stocks To Watch Heading Into Tuesday - Benzinga
Verastem Oncology (VSTM) Shifts Focus to Promising KRAS G12D Inh - GuruFocus
Calkins, Verastem CFO, sells $628 in shares By Investing.com - Investing.com South Africa
Verastem Oncology provides update on Ramp 203 phase 1/2 clinical trial - marketscreener.com
Verastem Oncology Stock Drops After Hours After Discontinuing A Clinical Trial In Lung Cancer - Stocktwits
Verastem to Discontinue RAMP 203 Clinical Trial in Lung Cancer After Interim Data Read - MarketScreener
Verastem stock falls after discontinuing KRAS G12C lung cancer trial By Investing.com - Investing.com Nigeria
Verastem (VSTM) Shifts Focus to Promising KRAS G12D Inhibitor in Cancer Treatment - GuruFocus
Verastem stock falls after discontinuing KRAS G12C lung cancer trial - Investing.com
Verastem discontinues KRAS G12C lung cancer trial to focus on G12D - Investing.com Canada
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer - Business Wire
Calkins, Verastem CFO, sells $628 in shares - Investing.com India
Behavioral Patterns of VSTM and Institutional Flows - Stock Traders Daily
Verastem, Inc.'s (NASDAQ:VSTM) Stock Retreats 26% But Revenues Haven't Escaped The Attention Of Investors - 富途牛牛
Verastem, Inc.'s (NASDAQ:VSTM) Share Price Is Still Matching Investor Opinion Despite 26% Slump - simplywall.st
Is Verastem Inc a good long term investmentAI-Driven Market Analysis & Double Digit Wealth Tips - earlytimes.in
Will Verastem Inc. stock outperform Nasdaq indexJuly 2025 Final Week & Consistent Profit Trade Alerts - Улправда
Verastem (STU:2VS) EV-to-OCF : -3.85 (As of Dec. 20, 2025) - GuruFocus
Can Verastem Inc. stock surprise with earnings upsideQuarterly Portfolio Review & Low Risk Entry Point Guides - Улправда
Squarepoint Ops LLC Boosts Stake in Verastem, Inc. $VSTM - MarketBeat
Can Verastem Inc. stock sustain revenue growthJuly 2025 News Drivers & AI Powered Buy/Sell Recommendations - Улправда
Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Mizuho maintains Verastem stock outperform with $9 target - MSN
Is Verastem Inc. stock vulnerable to regulatory risksQuarterly Growth Report & Low Risk High Win Rate Stock Picks - Улправда
Verastem streamlines leadership team amid strategic transition - MSN
Verastem, Inc. Announces Departure of Chief Operating Officer - TradingView — Track All Markets
Why Verastem Inc. stock could benefit from AI revolutionGDP Growth & Fast Exit Strategy with Risk Control - bolumsonucanavari.com
How Verastem Inc. (2VSA) stock moves in volatile trading sessionsJuly 2025 Patterns & Real-Time Buy Signal Alerts - Улправда
Will Verastem Inc. stock benefit from green energy trendsQuarterly Growth Report & Expert Approved Momentum Trade Ideas - Улправда
Verastem Inc (VSTM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Verastem Inc 주식 (VSTM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Stuglik Brian M | Director |
Dec 16 '25 |
Sale |
9.14 |
592 |
5,411 |
101,147 |
| Paterson Dan | President and CEO |
Dec 16 '25 |
Sale |
9.14 |
393 |
3,592 |
410,425 |
| Gagnon Robert E. | Director |
Dec 16 '25 |
Sale |
9.14 |
283 |
2,587 |
41,678 |
| Paterson Dan | President and CEO |
Dec 10 '25 |
Sale |
10.07 |
2,000 |
20,140 |
412,818 |
| Paterson Dan | President and CEO |
Dec 11 '25 |
Sale |
10.00 |
2,000 |
20,000 |
410,818 |
| Paterson Dan | President and CEO |
Dec 05 '25 |
Sale |
10.61 |
2,000 |
21,220 |
418,818 |
| Paterson Dan | President and CEO |
Dec 08 '25 |
Sale |
10.50 |
2,000 |
21,000 |
416,818 |
| Paterson Dan | President and CEO |
Dec 09 '25 |
Sale |
10.25 |
2,000 |
20,500 |
414,818 |
0.90%
자본화:
|
볼륨(24시간):